BioNxt Solutions Management

Management criteria checks 3/4

BioNxt Solutions' CEO is Wolfgang Probst, appointed in Jul 2024, has a tenure of less than a year. directly owns 0.97% of the company’s shares, worth $229.84K. The average tenure of the management team and the board of directors is 2.5 years and 6 years respectively.

Key information

Wolfgang Probst

Chief executive officer

CA$175.2k

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	1.0%
Management average tenure	2.5yrs
Board average tenure	6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Wolfgang Probst's remuneration changed compared to BioNxt Solutions's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-CA$6m
Jun 30 2024	n/a	n/a	-CA$6m
Mar 31 2024	n/a	n/a	-CA$8m
Dec 31 2023	CA$175k	n/a	-CA$8m
Sep 30 2023	n/a	n/a	-CA$13m
Jun 30 2023	n/a	n/a	-CA$13m
Mar 31 2023	n/a	n/a	-CA$12m
Dec 31 2022	CA$128k	n/a	-CA$12m
Sep 30 2022	n/a	n/a	-CA$14m
Jun 30 2022	n/a	n/a	-CA$14m
Mar 31 2022	n/a	n/a	-CA$17m
Dec 31 2021	CA$216k	CA$216k	-CA$21m
Sep 30 2021	n/a	n/a	-CA$15m
Jun 30 2021	n/a	n/a	-CA$19m
Mar 31 2021	n/a	n/a	-CA$19m
Dec 31 2020	CA$184k	CA$184k	-CA$17m
Sep 30 2020	n/a	n/a	-CA$16m
Jun 30 2020	n/a	n/a	-CA$13m
Mar 31 2020	n/a	n/a	-CA$10m
Dec 31 2019	CA$178k	n/a	-CA$8m
Sep 30 2019	n/a	n/a	-CA$6m
Jun 30 2019	n/a	n/a	-CA$2m
Mar 31 2019	n/a	n/a	-CA$2m
Dec 31 2018	CA$61k	n/a	-CA$861k

Compensation vs Market: Wolfgang's total compensation ($USD123.79K) is below average for companies of similar size in the US market ($USD649.07K).

Compensation vs Earnings: Wolfgang's compensation has increased whilst the company is unprofitable.

CEO

Wolfgang Probst (43 yo)

less than a year

Tenure

CA$175,164

Compensation

Mr. Wolfgang Probst is a Co-Founder at BioNxt Solutions Inc. and serves as its Interim Chief Executive Officer since July 1, 2024. Mr. Probst serves as a Director at BioNxt Solutions Inc. (formerly known a...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Wolfgang Probst	Co-Founder	less than a year	CA$175.16k	0.97% $ 229.8k
Hugh A. Rogers	Co-Founder & Director	no data	CA$188.91k	0.63% $ 148.3k
Raimar Lobenberg	Co-Founder & Director	no data	CA$60.00k	4.41% $ 1.0m
Patrick Meagher	CFO, Corporate Secretary & Director	3.1yrs	CA$78.00k	0.023% $ 5.4k
Florian Sahr	Head of Project Management	2.5yrs	no data	no data
Wolfgang Wagner	Head of Research & Development	no data	no data	no data

2.5yrs

Average Tenure

43.5yo

Average Age

Experienced Management: BNXT.F's management team is considered experienced (2.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Wolfgang Probst	Co-Founder	6yrs	CA$175.16k	0.97% $ 229.8k
Hugh A. Rogers	Co-Founder & Director	7yrs	CA$188.91k	0.63% $ 148.3k
Raimar Lobenberg	Co-Founder & Director	6yrs	CA$60.00k	4.41% $ 1.0m
Patrick Meagher	CFO, Corporate Secretary & Director	1.3yrs	CA$78.00k	0.023% $ 5.4k

6.0yrs

Average Tenure

43.5yo

Average Age

Experienced Board: BNXT.F's board of directors are considered experienced (6 years average tenure).

BioNxt Solutions Management

Management criteria checks 3/4

Key information

Recent management updates

BioNxt Solutions Inc., Annual General Meeting, Nov 01, 2024

BioNxt Solutions Inc. Announces Change of Directors

XPhyto Therapeutics Corp., Annual General Meeting, Oct 12, 2022

Xphyto Therapeutics Corp. Adds Dr. Flon A. Sahr to Its European Teateam as Head of Project Management

Recent updates

BioNxt Solutions Inc. Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity

BioNxt Solutions Inc. announced that it expects to receive CAD 3 million in funding

Bionxt Solutions Inc. Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent

BioNxt Solutions Inc. Receives Positive International Examination Report from the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases

BioNxt Solutions Inc., Annual General Meeting, Nov 01, 2024

BioNxt Solutions Inc. announced that it has received CAD 0.945 million in funding

BioNxt Solutions Inc. Announces ODF Cladribine Update

BioNxt Solutions Inc. Reports Commercialization of Odf Cladribine Product for MS Next Steps

BioNxt Solutions Inc. Reports Successful Results from ODF Cladribine PK Study

BioNxt Solutions Inc. Reports Successful Results from Odf Cladribine Toxicity Study

BioNxt Solutions Inc. announced that it has received CAD 1.168 million in funding

BioNxt Solutions Inc. announced that it expects to receive CAD 2.4 million in funding

BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing

BioNxt Solutions Inc Reports on New Cladrabine Odf Product Development and Commercialization Program

BioNxt Solutions Inc. Announces Change of Directors

BioNxt Solutions Inc. announced that it expects to receive CAD 3.975 million in funding

Bionxt Solutions Inc. Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson's Disease

BioNxt Solutions Inc. Reports Update on Commercialization of Rotigotine Patch for Treatment of Parkinson's Disease

BioNxt Solutions Inc. announced that it has received CAD 2.808 million in funding

BioNxt Solutions Inc. announced that it expects to receive CAD 2.6 million in funding

XPhyto Reports Excellent Rotigotine In-Vitro/Ex-Vivo Results for Parkinson's Disease Treatment

Xphyto Therapeutics Corp. Completes Rotigotine Transdermal Patch Optimization and Comparative Skin Absorption Study

XPhyto Therapeutics Corp. Files Patent Application for Library of Novel Psychedelic Compounds

XPhyto Therapeutics Corp. announced that it has received CAD 3.6 million in funding

XPhyto Therapeutics Corp., Annual General Meeting, Oct 12, 2022

XPhyto Therapeutics Corp. announced that it expects to receive CAD 3.6 million in funding

Xphyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-Related Dental Disease

Xphyto Therapeutics Corp. Adds Dr. Flon A. Sahr to Its European Teateam as Head of Project Management

XPhyto Therapeutics Corp. (CNSX:XPHY) completed the acquisition of 3a-diagnostics GmbH.

XPhyto Therapeutics Corp. announced that it has received CAD 7 million in funding

XPhyto Provides Progress Report on Mescaline Program for Psychedelic Therapies

Max Pharma GmbH to Launch the Sale of 25-minute SARS-CoV- 2 (COVID-19) RT-PCR test system in Germany

XPhyto Therapeutics Corp. Provides Update on Drug Formulation and Development Business

XPhyto Therapeutics Corp. Establishes Proof of Concept Station for Point-Of-Care 25-Minute Covid-19 PCR Test in Germany

XPhyto Therapeutics Corp. and 3a-diagnostics GmbH Announces European Approval for 25 Minute Covid-19 PCR Test

XPhyto Therapeutics Corp. Builds Commercial Team to Launch 25-Minute Covid-19 RT-PCR Test

XPhyto Therapeutics Corp. Places First Order for 25-Minute Covid-19 RT-PCR Tests

Xphyto Builds Commercial Team to Launch 25-Minute COVID-19 RT-PCR TEST

XPhyto European CE-IVD Application for 25-Minute COVID-19 RT-PCR Test

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age